The authors collected 291 patients with a chromophobe kidney cancer who had undergone surgery at 16 academic centers. With a median follow-up of 44 months, 25/291 patients (8.6%) had disease recurrence and 18/291 patients (6.2%) had died from disease. Therefore, the 5- and 10-year cancer-specific survival rates were 93% and 88.9%. The only independent clinical predictors for cancer-specific survival were gender and clinical tumor stage. Pathologic features with statistical significance were tumor stage, N/M stage and sarcomatoid differentiation. It was concluded that chromophobe kidney cancer has a low potential to progress.
This study confirms published data that chromophobe kidney cancer is associated with a very good prognosis.
Presented by Alessandro Volpe, MD, et al. at the 26th Annual European Association of Urology (EAU) Congress - March 18 - 21, 2011 - Austria Centre Vienna, Vienna, Austria
Reported for UroToday by Christian Doehn, MD, PhD, Department of Urology, University of Lübeck Medical School, Lübeck Germany.
View EAU 2011 Annual Meeting Coverage
